Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

12.7K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
12.7K
Inflammatory Response01:28

Inflammatory Response

19.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
19.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

758
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
758
Inflammation01:38

Inflammation

64.4K
Overview
64.4K
T Cell Types and Functions01:24

T Cell Types and Functions

3.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

676
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
676

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysregulation of complement at the synapse in P301S mice and human tauopathies.

Acta neuropathologica communications·2026
Same author

Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID.

Immunology·2026
Same author

Absence of complement terminal pathway activity in C6-deficient mice prolongs survival in a mouse model of severe malarial infection.

Immunobiology·2025
Same author

CD59, Disulphide-Locked Human C9 and Horse C9 Inhibit Human Membrane Attack Complex Assembly by Similar Mechanisms.

Immunology·2025
Same author

Complement dysregulation in human tauopathies.

Brain pathology (Zurich, Switzerland)·2025
Same author

Plasma complement system markers and their association with cardiometabolic risk factors: an ethnic comparison of White European and Black African men.

American journal of physiology. Endocrinology and metabolism·2025

Related Experiment Video

Updated: Mar 31, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Complement, a target for therapy in inflammatory and degenerative diseases.

B Paul Morgan1, Claire L Harris1,2

  • 1Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Nature Reviews. Drug Discovery
|October 24, 2015
PubMed
Summary

The complement system, crucial for immunity, can cause harm when overactivated. This review explores anti-complement therapies targeting diseases driven by complement dysregulation.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
In Vivo Imaging Uncovers the Migratory Behavior of Leukocytes within the Joints
10:10

In Vivo Imaging Uncovers the Migratory Behavior of Leukocytes within the Joints

Published on: December 9, 2025

775

Related Experiment Videos

Last Updated: Mar 31, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
In Vivo Imaging Uncovers the Migratory Behavior of Leukocytes within the Joints
10:10

In Vivo Imaging Uncovers the Migratory Behavior of Leukocytes within the Joints

Published on: December 9, 2025

775

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • The complement system is a vital part of innate immunity, defending against pathogens.
  • However, uncontrolled complement activation can lead to inflammation, tissue damage, and various diseases.

Purpose of the Study:

  • To review the history, current status, and future prospects of anti-complement therapies.
  • To highlight the complement system as a target for drug development.

Main Methods:

  • Review of existing literature on complement biology and anti-complement drugs.
  • Analysis of the complement cascade, its components, and regulatory mechanisms.
  • Examination of therapeutic strategies targeting complement.

Main Results:

  • The complement system offers multiple drug development targets due to its complex cascade, proteases, and receptors.
  • Currently, only two anti-complement drugs are approved, but numerous others are in development.
  • Therapies are being developed for infectious, inflammatory, degenerative, traumatic, and neoplastic disorders.

Conclusions:

  • The complement system's dual role in defense and disease makes it a significant therapeutic target.
  • Advancements in structural biology facilitate the design of novel anti-complement drugs.
  • The field of anti-complement therapy is rapidly expanding with promising future directions.